Court: Drug Maker May Sue Compounder Under State Statutes

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Fifth Circuit: Maker of FDA-Approved Drug May Sue Compounder Under State Unfair Competition Statutes

Dennis Tosh

April 16, 2025 at 02:20 PM EST

Reversing a district court ruling, a federal appeals court has allowed a suit filed under state unfair competition laws by a manufacturer of an FDA-approved drug against a company selling a compounded version of the drug to proceed (Zyla Life Sciences, L.L.C. v. Wells Pharma of Houston, L.L.C., 134 F.4th 326 (5th Cir. 2025)). Zyla Life Sciences L.L.C. sells Indocin brand supp... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Fifth Circuit: Maker of FDA-Approved Drug May Sue Compounder Under State Unfair Competition Statutes

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT